Prognostic significance of NRAS gene mutations in children with acute myelogenous leukemia

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 3, Issue 1, 2011, Pages

  Aly, Rabab M ^a   El sharnoby, Mohamed R ^b   Hagag, Adel A ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b TANTA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904264998     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2011.055     Document Type: Article

References (38)

1. DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542. http://dx.doi.org/10.1182/blood-2002-02-0492PMid:12176867
2. Ritter M, Kim TD, Lisske P, Thiede C, Schaich M, Neubauer A. Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia. Haematologica 2004 89: 1397-1399. PMid:15531466
3. Bachas C, Schuurhuis GJ, Hollink IH, Kwidama ZJ, Goemans BF, Zwaan CM, van den Heuvel-Eibrink MM, de Bont ES, Reinhardt D, Creutzig U, de Haas V, Assaraf YG, Kaspers GJ, Cloos J. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood. 2010 Oct 14;116(15):2752-8. Epub 2010 http://dx.doi.org/10.1182/blood-2010-03-276519 PMid:20592250
4. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001 Jan 1;97(1):89-94 http://dx.doi.org/10.1182/blood. V97.1.89PMid:11133746
5. Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG, Bernstein ID, Arceci RJ, Radich JP. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood. 2003 Aug 15;102(4):1474-9. http://dx.doi.org/10.1182/blood-2003-01-0137 PMid: 12702504
6. Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M, Willasch A, Kaspers GJ, Trka J, Baruchel A, de Graaf SS, Creutzig U, Pieters R, Reinhardt D, Zwaan CM. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood. 2009 Jun 4;113 (23):5951-60. http://dx.doi.org/10.1182/blood-2008-09-177949 PMid:19171881
7. Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B, Franklin JL, Lange B, Meshinchi S. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2010 Aug 5;116 (5):702-10, http://dx.doi.org/10.1182/blood-2010-02-268953 PMid:20413658 PMCid:2918327
8. Lubbert M, Mirro J Jr., Kitchingman G, et al. Prevalence of Nras mutations in children with myelodysplastic syndromes and acute myeloid leukemia. Oncogene. 1992;7:263-268. PMid: 1549347
9. Hirai H. Molecular Mechanisms of Myelodysplastic Syndrome. Jpn. J. Clin. Oncol 2003;33 (4): 153-160. http://dx.doi.org/10.1093/jjco/hyg037PMid:12810828
10. Bowen D, Frew M, Hills R et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 2005; 106: 2113-2119. http://dx.doi.org/10.1182/blood-2005-03-0867 PMid:15951308
11. Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hählen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia. 2005 Sep;19(9):1536-42. http://dx.doi.org/10.1038/sj.leu.2403870PMid:16015387
12. Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol. 1999;17:1071-1079. PMid:10071302
13. Illmer T, Thiede C, Fredersdorf A et al. Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts. Clin Cancer Res 2005; 11: 3217-3224. http://dx.doi.org/10.1158/1078-0432.CCR-04-2232 PMid: 15867216
14. Padua RA, West RR. Oncogene mutation and prognosis in the myelodysplastic syndromes. Br J Haematol 2000; 111:873-874. http://dx.doi.org/10.1046/j.1365-2141.2000.02472.x PMid: 11122149
15. Paquette RL, Landaw EM, Pierre RV et al. N-Ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993;82: 590-599 PMid: 8329714
16. Lapillonne H, Liopis L, Auvrignon A, Renneville A, Labopin M, Mazingue F, Perot C, et al. Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia. Leukemia 2010; 24, 205-209. http://dx.doi.org/10.1038/leu.2009.172 PMid: 19759559
17. Radich JP, Kopecky KJ, Willman CL et al. N-Ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood 1990; 76:801-807. PMid:2200539
18. Mitelman F (ed). (1991). An international system for human cytogenetic nomenclature. Karger: Basel, 1991.
19. Schaich M, Ritter M, Illmer T, et al. Mutations in ras protooncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol 2001; 112: 300-307. http://dx.doi.org/10.1046/j.1365-2141.2001.02562.x PMid: 11167822
20. Vogelstein B, Civin CI, Preisinger AC, et al. RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study. Genes Chromosomes Cancer 1990; 2: 159-162. http://dx.doi.org/10.1002/gcc.2870020212
21. Liang DC, Shih LY, Fu JF, et al. K-ras mutations and N-ras mutations in childhood acute leukemias with or without mixedlineage leukemia gene rearrangements. Cancer 2006; 106: 950-956. http://dx.doi.org/10.1002/cncr.21687 PMid: 16404744
22. Valk PJM, Bowen DT, Frew ME, et al. Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16) [abstract]. Haematologica 2004; 89:106. PMid:14754614
23. Beghini A, Peterlongo P, Ripamonti CB, et al. C-kit mutation in core binding factor leukemias. Blood 2000; 95:726-727. PMid: 10660321
24. Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, Wheatley K, de Graaf SS, van den Berg E, Burnett AK, Gibson BE. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010 Jun 1;28(16):2674-81. Epub 2010 http://dx.doi.org/10.1200/JCO.2009.24.8997 PMid:20439644
25. von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, Zemanova Z, Stary J, Bourquin JP, Haas OA, Dworzak MN, Creutzig U. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010 Jun 1;28(16):2682-9. http://dx.doi.org/10.1200/JCO.2009.25.6321 PMid:20439630
26. Bachas C, Schuurhuis GJ, Hollink IH, Kwidama ZJ, Goemans BF, Zwaan CM, van den Heuvel-Eibrink MM, de Bont ES, Reinhardt D, Creutzig U, de Haas V, Assaraf YG, Kaspers GJ, Cloos J. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood. 2010 Oct 14;116(15):2752-8. http://dx.doi.org/10.1182/blood-2010-03-276519 PMid:20592250
27. Balgobind BV, Hollink IH, Arentsen-Peters ST, Zimmermann M, Harbott J, Beverloo B, von Bergh AR, Cloos J, Kaspers GJ, de Haas V, Zemanova Z, Stary J, Cayuela JM, Baruchel A, Creutzig U, Reinhardt D, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica. 2011, 96(10): 1478-1487 http://dx.doi.org/10.3324/haematol.2010.038976 PMid:21791472 PMCid:3186309
28. Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 1996; 14:204. PMid:8558199
29. Miyawaki S, Tanimoto M, Kobayashi T, Minami S, et al. Randomized study of individualized induction therapy with or without etoposide in adult acute myeloid leukemia (except for M3) (JALSG-AML92 study) and analysis of prognostic factors. Blood 1997; 90:503a.
30. Mro'zek K, Heinonen K, de la Chapelle A, Bloomfield CD Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997; 24:17. PMid:9045301
31. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zandwijk N, Mooi WJ, Bos JL, Rodenhuis S K-RAS oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323;9: 561-565. http://dx.doi.org/10.1056/NEJM199008303230902 PMid:2199829
32. Lübbert M, Mirro J Jr, Miller CW, Kahan J, Issac G, Kitchingman G, Mertelsmann R, Herrmann F, McCormick F, Koeffler HP N-Ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood 1990; 75:1163-1169. PMid:2407301
33. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994;83:1603-11. PMid:8123851
34. Coghlan DW, Morley AA, Matthews JP, Bishop JF. The incidence and prognostic significance of mutations in codon 13 of the Nras gene in acute myeloid leukemia. Leukemia 1994;: 1682-7. PMid:7934163
35. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074-80. PMid: 10216104
36. De Melo MB, Lorand-Metze I, Lima CS, Saad ST, Costa FF Nras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis. Leuk Lymphoma. 1997;24:309-17. PMid:9156660
37. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001;97:3589-95. http://dx.doi.org/10.1182/blood. V97.11.3589 PMid: 11369655
38. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004;113:528-38. PMid: 14966562 PMCid:33826